Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases. )--Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases.
Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases. )--Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases.
